Apimeds Pharmaceuticals US, Inc. (APUS)

APUS Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-1.39	-0.78	-0.67	-1.03
Stock-Based Compensation	-	0.07	0.19	0.19
Other Operating Activities	0.12	0.04	0.03	0.01
Change in Accounts Payable	0.54	0.05	-0	0
Change in Other Net Operating Assets	0	-0.01	0	-0
Operating Cash Flow	-0.73	-0.63	-0.45	-0.82
Short-Term Debt Issued	0.33	0.01	0.28	-
Long-Term Debt Issued	-	-	-	0.4
Total Debt Issued	0.33	0.01	0.28	0.4
Short-Term Debt Repaid	-	-0.03	-	-
Total Debt Repaid	-	-0.03	-	-
Net Debt Issued (Repaid)	0.33	-0.02	0.28	0.4
Issuance of Common Stock	-	1.06	-	-
Financing Cash Flow	0.33	1.03	0.28	0.4
Net Cash Flow	-0.41	0.4	-0.17	-0.42
Levered Free Cash Flow	-0.29	-0.35	-0.2	-
Unlevered Free Cash Flow	-0.22	-0.32	-0.18	-
Change in Net Working Capital	-0.58	-0.07	-0.03	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q